Skip to main content
Caplight Logo









Rigerna Therapeutics

Rigerna Therapeutics

Private
SuzhouHealthcare & Life Scienceshttps://www.rigerna.com/

Last Round

Early Funding

Apr 2, 2026

Total Funding Raised

$60M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Rigerna Therapeutics is a biotechnology company that develops nucleic acid drugs and siRNA therapies intended to treat liver and non-liver diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

siRNA therapyRNAi therapygene silencingIgA nephropathyIgANkidney disease therapyoligonucleotide therapyC3 inhibitormetabolic disease therapysiRNA deliverycomplement inhibitordrug delivery platformclinical-stage biotechnucleotide modificationdrug licensingkidney-targeting platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rigerna Therapeutics Comparables

Compare Rigerna Therapeutics with similar companies based on industry and business-model similarity.

Rigerna Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rona Therapeutics
88%
Borealis Biosciences
84%
Argo Biopharma
83%

Rigerna Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 2, 2026
SeedOct 1, 2024

Key People

Founding team and executive leadership

Ryan Yuanyu HUANG

Chairman, Chief Scientist Officer, Founder

Founding Team

Haitao Li

Chief Technology Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 327% MoM.

  • Apr 2, 2026

    $30M raised in early funding.

Rigerna Therapeutics Filings

Explore SEC and related filing metadata, where available.

Rigerna Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Rigerna Therapeutics's valuation, stock price, and market status.

Is Rigerna Therapeutics a public or private company?

Rigerna Therapeutics is a private company.

What is the current stock price of Rigerna Therapeutics?

Rigerna Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Rigerna Therapeutics worth (valuation)?

Valuation information for Rigerna Therapeutics is not publicly available.

Can I buy Rigerna Therapeutics stock?

Rigerna Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Rigerna Therapeutics's last funding round?

Rigerna Therapeutics's most recent funding round was Early Funding on April 2, 2026.

Who are the main investors in Rigerna Therapeutics?

Investor information for Rigerna Therapeutics is not publicly disclosed.

Will Rigerna Therapeutics IPO soon?

No public IPO plans have been announced for Rigerna Therapeutics.

How can I track Rigerna Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rigerna Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSuzhou
Employee Range5
Year Founded2022
Last FundingApr 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?